Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of JYB1904 in adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines
CTR20260236Phase 3Active
- Sponsor
- Jiangsu Jiye Biopharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing JYB1904 with Placebo then JYB1904 (2 arms). Primary endpoint: Change from baseline in UAS7 at Week 12. Started Mar 2026; status: active.
02
Drugs
ozureprubart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20260236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260236.